{
     "PMID": "12044798",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20030127",
     "LR": "20131121",
     "IS": "0014-2999 (Print) 0014-2999 (Linking)",
     "VI": "443",
     "IP": "1-3",
     "DP": "2002 May 17",
     "TI": "Improved efficacy of fluoxetine in increasing hippocampal 5-hydroxytryptamine outflow in 5-HT(1B) receptor knock-out mice.",
     "PG": "99-104",
     "AB": "To test for the contribution of the 5-HT(1B) receptor subtype in mediating the effects of fluoxetine, a selective serotonin reuptake inhibitor (SSRI), we used intracerebral in vivo microdialysis in awake, freely moving 5-HT(1B) receptor knock-out mice. We show that a single systemic administration of fluoxetine (1, 5 or 10 mg/kg, i.p.) increased extracellular serotonin levels [5-HT](ext) in the ventral hippocampus and frontal cortex of wild-type and mutant mice. However, in the ventral hippocampus, fluoxetine, at the three doses studied, induced a larger increase in [5-HT](ext) in knock-out than in wild-type mice. In the frontal cortex, the effect of fluoxetine did not differ between the two genotypes. The region-dependent response to fluoxetine described here in mutants confirms data we recently reported for another SSRI, paroxetine. These data suggest that 5-HT(1B) autoreceptors limit the effects of selective serotonin reuptake inhibitors on dialysate 5-HT levels at serotonergic nerve terminals located mainly in the ventral hippocampus. Alternative mechanisms, e.g., changes in 5-HT transporter and/or 5-HT(1A) receptor density in 5-HT(1B) receptor knock-out mice could also explain these findings.",
     "FAU": [
          "Malagie, Isabelle",
          "David, Denis J",
          "Jolliet, Pascale",
          "Hen, Rene",
          "Bourin, Michel",
          "Gardier, Alain M"
     ],
     "AU": [
          "Malagie I",
          "David DJ",
          "Jolliet P",
          "Hen R",
          "Bourin M",
          "Gardier AM"
     ],
     "AD": "Laboratoire de Neuropharmacologie UPRES EAD MENRT, Faculte de Pharmacie IFR-ISIT Institut de Signalisation et d'Innovation Therapeutique, Universite Paris-Sud, Tour D1 2eme etage 5 rue 1-B.Clement, 92296, Chatenay-Malabry cedex, France.",
     "LA": [
          "eng"
     ],
     "PT": [
          "Comparative Study",
          "Journal Article",
          "Research Support, Non-U.S. Gov't"
     ],
     "PL": "Netherlands",
     "TA": "Eur J Pharmacol",
     "JT": "European journal of pharmacology",
     "JID": "1254354",
     "RN": [
          "0 (Autoreceptors)",
          "0 (Receptor, Serotonin, 5-HT1B)",
          "0 (Receptors, Serotonin)",
          "0 (Serotonin Uptake Inhibitors)",
          "01K63SUP8D (Fluoxetine)",
          "333DO1RDJY (Serotonin)"
     ],
     "SB": "IM",
     "MH": [
          "Animals",
          "Autoreceptors/*drug effects/genetics",
          "Fluoxetine/*pharmacology",
          "Frontal Lobe/drug effects/metabolism",
          "Hippocampus/*drug effects/metabolism",
          "Injections, Intraperitoneal",
          "Male",
          "Mice",
          "Mice, Knockout",
          "Microdialysis",
          "Receptor, Serotonin, 5-HT1B",
          "Receptors, Serotonin/*drug effects/genetics",
          "Serotonin/*metabolism",
          "Serotonin Uptake Inhibitors/*pharmacology"
     ],
     "EDAT": "2002/06/05 10:00",
     "MHDA": "2003/01/28 04:00",
     "CRDT": [
          "2002/06/05 10:00"
     ],
     "PHST": [
          "2002/06/05 10:00 [pubmed]",
          "2003/01/28 04:00 [medline]",
          "2002/06/05 10:00 [entrez]"
     ],
     "AID": [
          "S0014299902016047 [pii]"
     ],
     "PST": "ppublish",
     "SO": "Eur J Pharmacol. 2002 May 17;443(1-3):99-104.",
     "term": "hippocampus"
}